CommercialCoverageHigh impact
08.01.36h, Therapies for Spinal Muscular Atrophy Nusinersen (Spinraza®) and Onasemnogene abeparvovec-xioi (Zolgensma®)
Independence Blue Cross·Neurology, Pediatrics, Pharmacy·Pharmacy
Effective date
Jul 1, 2026
We identified it
Jul 2, 2026
Summary
This is a brand-new pharmacy policy (effective 07/01/2026) governing coverage and billing for two spinal muscular atrophy (SMA) therapies: Nusinersen (Spinraza®) and Onasemnogene abeparvovec-xioi (Zolgensma®). The billing team must immediately obtain and review the full policy details to understand any prior authorization requirements, coverage criteria, allowed patient populations, and billing code assignments for these specialty medications.
Action Required
By 06/15/2026: Billing team must obtain the complete policy text from the source URL and review all coverage criteria, prior authorization requirements, and applicable billing codes for Nusinersen (Spinraza®) and Onasemnogene abeparvovec-xioi (Zolgensma®). Update billing system rules, prior authorization workflows, and clinical documentation requirements accordingly. Coordinate with providers and clinical staff to ensure understanding of medical necessity documentation requirements. By 07/01/2026: Implement all system changes and ensure front-desk and authorization staff are trained on new requirements. Claims submitted without meeting policy requirements will be denied.